We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Importance of Glucagon-Like Peptide-2 (GLP-2)in Mesenteric Bloodflow in Humans

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2005 by Glostrup University Hospital, Copenhagen.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00273000
First Posted: January 9, 2006
Last Update Posted: September 11, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Rigshospitalet, Denmark
University of Copenhagen
Information provided by:
Glostrup University Hospital, Copenhagen
  Purpose
The purpose of this study is to study the effect of GLP-2 on mesenteric bloodflow in healthy adults by the use of ultrasound., it is the hypothesis that GLP-2 vil increase the bloodflow.

Condition Intervention
Healthy Drug: GLP-2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: The Importance of Glucagon-Like Peptide-2 (GLP-2)in Mesenteric Bloodflow in Humans

Resource links provided by NLM:


Further study details as provided by Glostrup University Hospital, Copenhagen:

Estimated Enrollment: 10
Study Start Date: January 2006
Detailed Description:

The investigation will include 10 testpersons.

It will be a 2 fase study over 2 days.

day 1: The testperson will meet fasting, and take in a standard liquid meal, after this the bloodflow in a mesenteric artery will be measured by use of ultrasonic technique. Bloodsamples will be taken regular in a total wolumne of 200 ml.

day 2:The testperson will meet fasting, there wil be administered intraveneous GLP-2 in 3 increasing doses over 3 x 45 min.and one subcutaneous dose. During this the bloodflow in a mesenteric artery will be measured by use of ultrasonic technique. Bloodsamples will be taken regular in a total wolumne of 200 ml.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy

Exclusion Criteria:

  • use of drugs
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00273000


Contacts
Contact: Lasse Bremholm Hansen, MD 004560927874 hoersted-bremholm@webspeed.dk

Locations
Denmark
Rigshospitalet Recruiting
Copenhagen, Copenhagen City, Denmark, 2100
Contact: Lasse Bremholm Hansen, MD    004560927874    hoersted-bremholm@webspeed.dk   
Sub-Investigator: Mads Hornum, MD         
Sponsors and Collaborators
Glostrup University Hospital, Copenhagen
Rigshospitalet, Denmark
University of Copenhagen
Investigators
Principal Investigator: Mads Hornum, MD Glostrup University Hospital, Copenhagen
  More Information

ClinicalTrials.gov Identifier: NCT00273000     History of Changes
Other Study ID Numbers: GLP-2, MBF
First Submitted: January 6, 2006
First Posted: January 9, 2006
Last Update Posted: September 11, 2006
Last Verified: October 2005

Additional relevant MeSH terms:
Glucagon
Glucagon-Like Peptide 1
Gastrointestinal Agents
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Incretins